{"abstract":"The Food and Drug Administration (FDA) has determined that OPANA ER (oxymorphone hydrochloride (HCl)) Extended-Release Tablet products approved under new drug application (NDA) 21-610 were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs for oxymorphone HCl extended-release tablets if all other legal and regulatory requirements are met.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/06/25/2013-15099.html","cfr_references":[],"citation":"78 FR 38053","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":null,"disposition_notes":null,"docket_ids":["Docket No. FDA-2012-P-0895"],"dockets":[],"document_number":"2013-15099","effective_on":null,"end_page":38053,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/06/25/2013-15099.xml","html_url":"https://www.federalregister.gov/documents/2013/06/25/2013-15099/determination-that-opana-er-oxymorphone-hydrochloride-drug-products-covered-by-new-drug-application","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-15099?publication_date=2013-06-25","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-06-25/2013-15099/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":888,"last_updated":"2026-07-26 12:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-06-25/pdf/2013-15099.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-15099.pdf?1372078524","publication_date":"2013-06-25","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/06/25/2013-15099.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[{"title":"Endo Pharmaceuticals - Supplement","document_id":"FDA-2012-P-0895-0011"},{"title":"Endo Pharmaceuticals Inc - Supplement re FDA-2012-P-0895-0001","document_id":"FDA-2012-P-0895-0010"}],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2012-P-0895","supporting_documents_count":2,"docket_id":"FDA-2012-P-0895","regulation_id_number":null,"title":"Take the Actions Described In the Peitition With Respect to Endo's Discontinued Opana® ER (OxymorphoneHCI) Extended-Release Tablets - CLOSED","checked_regulationsdotgov_at":"2013-07-15T06:00:15Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":38053,"subtype":null,"title":"Determination That OPANA ER (Oxymorphone Hydrochloride) Drug Products Covered by New Drug Application 21-610 Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness","toc_doc":"OPANA ER (Oxymorphone Hydrochloride)","toc_subject":"Determinations:","topics":[],"type":"Notice","volume":78}